Family Office Real Estate Daily · Family Office Real Estate Research Desk · Preview
Research Desk
A curated index of 20,204 CRE market research reports from the major institutional publishers — filterable by asset class, market and publisher. Editorial Family-Office interpretation layer is rolling out report-by-report.
Showing Family Office Briefings with a Co-GP / Platform angle — each card surfaces how a family office could deploy capital in that market.
9 reports
Page 1 / 1- Cushman & WakefieldMay 6, 2025
Q1 2025 Raleigh Life Sciences Report
Co-GP / Platform:A family office could deploy into the Raleigh life sciences market by backing a sponsor or operator at the GP level, sharing in the promote and benefiting from their expertise.
- Cushman & WakefieldMar 25, 2025
Q4 2024 Raleigh Life Sciences Report
Co-GP / Platform:A family office could deploy into the Raleigh life sciences market by backing a sponsor or operator at the GP level, sharing in the promote and benefiting from their expertise.
- Cushman & WakefieldMar 25, 2025
Q4 2024 Boston Life Sciences Report
Co-GP / Platform:A family office could deploy into the Boston life sciences market by backing a sponsor or operator at the GP level, sharing in the promote and benefiting from their expertise.
- Cushman & WakefieldNov 27, 2024
Q3 2024 Raleigh Life Sciences Report
Co-GP / Platform:A family office could deploy into the Raleigh life sciences market by backing a sponsor/operator at the GP level to share in the promote and benefit from a repeatable pipeline.
- Cushman & WakefieldAug 2, 2024
Q2 2024 Raleigh Life Sciences Report
Co-GP / Platform:A family office could deploy into the Raleigh life sciences market by backing a sponsor/operator at the GP level, focusing on co-GP or JV equity to capitalize on growth opportunities.
- Cushman & WakefieldMay 3, 2024
Q1 2024 Raleigh Life Sciences Report
Co-GP / Platform:A family office could deploy into the Raleigh life sciences market by backing a sponsor/operator at the GP level to share in the promote and benefit from their expertise.
- Cushman & WakefieldFeb 2, 2024
Q4 2023 Raleigh Life Sciences Report
Co-GP / Platform:A family office could deploy into the Raleigh life sciences market by backing a sponsor or operator at the GP level, focusing on co-GP or JV equity to capitalize on growth.
- Cushman & WakefieldNov 10, 2023
Q3 2023 Raleigh Life Sciences Report
Co-GP / Platform:A family office could deploy into the Raleigh life sciences market by backing a sponsor or operator at the GP level to share in the promote and benefit from a repeatable pipeline.
- Cushman & WakefieldAug 11, 2023
Q2 2023 Raleigh Life Science Report
Co-GP / Platform:A family office could deploy into the Raleigh life science market by backing a sponsor/operator at the GP level to share in the promote and benefit from a repeatable pipeline.
Research Hubs
Dedicated pages for every major publisher and market — each with aggregated KPI medians, asset-class breakdowns and the latest reports, read through a family-office lens.